Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia (AML)

Inhibition of cholesterol synthesis and uptake sensitizes acute myeloid leukemia (AML) blasts to chemotherapy. A Phase 2 study of high dose pravastatin given in combination with idarubicin and cytarabine demonstrated an impressive response rate [75% complete remission (CR), CR with incomplete count...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leuk Res
Autors principals: Advani, Anjali S., Li, Hongli, Michaelis, Laura C., Medeiros, Bruno C., Liedtke, Michaela, List, Alan F., O’Dwyer, Kristen, Othus, Megan, Erba, Harry P., Appelbaum, Frederick R.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6574123/
https://ncbi.nlm.nih.gov/pubmed/29407182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2018.01.021
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars